Rockwell Medical (NASDAQ:RMTI - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.03, Zacks reports. Rockwell Medical had a negative net margin of 10.09% and a negative return on equity of 39.17%. The firm had revenue of $22.68 million during the quarter, compared to the consensus estimate of $21.18 million. During the same quarter in the previous year, the company posted ($0.10) earnings per share. Rockwell Medical updated its FY 2024 guidance to EPS.
Rockwell Medical Price Performance
Shares of RMTI traded up $0.01 on Wednesday, hitting $1.71. The company's stock had a trading volume of 188,455 shares, compared to its average volume of 197,242. Rockwell Medical has a fifty-two week low of $1.16 and a fifty-two week high of $6.24. The company has a 50 day moving average price of $1.56 and a 200 day moving average price of $1.61. The company has a market capitalization of $50.21 million, a PE ratio of -4.45 and a beta of 1.21. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.73 and a quick ratio of 1.38.
Analyst Ratings Changes
Separately, HC Wainwright cut their target price on shares of Rockwell Medical from $11.00 to $9.00 and set a "buy" rating on the stock in a report on Monday, March 25th.
Get Our Latest Stock Report on RMTI
Rockwell Medical Company Profile
(
Get Free Report)
Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.
Read More
Before you consider Rockwell Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rockwell Medical wasn't on the list.
While Rockwell Medical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
